Addressing CV risk: the role of statins and ezetimibe

Media formats available:

APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
ACC.24
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
- Brian Bergmark, MD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
ACC.24
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
- Michael Koren, MD
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
ACC.24
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
- Michael Gibson, MD
Characteristics of patients with DM using icosapent ethyl in the real world
Characteristics of patients with DM using icosapent ethyl in the real world
Dyslipidemia
Characteristics of patients with DM using icosapent ethyl in the real world
- Om P. Ganda, MD

PACE-CME